OVERVIEW
Led by an expert panel, the audience will learn to navigate the current landscape of next-generation imaging in metastatic castration-resistant prostate cancer (mCRPC), before gaining new insights on emerging treatment options for patients with metastatic castration-resistant disease. This event will also feature interactive case-based discussions designed to bring more clarity and confidence in the management and care of patients with mCRPC.[bold]To participate in this Industry Session at EAU2022 in Amsterdam or virtually you must be registered for EAU2022.[bold]
TARGET AUDIENCE
This activity is intended for an international audience of non-US healthcare professionals, specifically those within the oncology care team, including oncologists, urologists, radiologists, and other oncology clinicians caring for patients with metastatic castration-resistant prostate cancer (mCRPC).
GOAL STATEMENT
The goal of this activity is to update clinicians on the latest data on imaging and treatment of mCRPC.
LEARNING OBJECTIVES
Upon completion of this activity, participants will: Have increased knowledge regarding the [LIST][ITEM]Latest clinical data on the role of imaging in the management of mCRPC[ITEM]Latest clinical data on novel treatment options in mCRPC[/LIST]Demonstrate greater confidence in their ability to [LIST] [ITEM]Select appropriate imaging modalities for the optimal management and care of patients with mCRPC[/LIST]
ACCREDITATION STATEMENT
The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.0 continuing professional development credits (CPD). [WEBMDGLOBAL]
RAI Amsterdam
Europaplein 24 - ROOM: Green Area, Room 2
Amsterdam, , 1078 GZ
The Netherlands
Supported by an independent educational grant from [bold]Advanced Accelerator Applications[/bold].